US 11160850
Compositions of human prothrombin and activated factor X for improving hemostasis in the treatment of bleeding disorders
granted A61KA61K38/4833A61K38/4846
Quick answer
US patent 11160850 (Compositions of human prothrombin and activated factor X for improving hemostasis in the treatment of bleeding disorders) held by Takeda Pharmaceutical Company Limited expires Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Nov 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 12
- CPC classes
- A61K, A61K38/4833, A61K38/4846, A61K38/54, A61P